医薬品開発プロジェクトの中止理由のおよそ4分の1は安全性の問題によるものであり、これは一次ファーマコロジーだけでなく、セカンダリーファーマコロジーに起因する場合もあります。To address secondary pharmacology, researchers typically screen their small molecule compounds against a broad panel of off-target receptors. The challenge is in interpreting the readouts to understand which receptor interactions will contribute to potential adverse effects in clinical development and post-marketing. This suffers from being opinion-based rather than evidence-based, and may not be applied consistently across projects, or over time, or among individuals.

Secondary Intelligence™ software is the only application of its kind that manages and visualizes secondary pharmacology readouts, provides information (including mechanistic information) on potential adverse effects and assesses the likelihood of them occurring.

In this webinar, Dr. Will Redfern will discuss:

• The depth of scientific knowledge, expert data curation and analysis embedded in the software
• How to use ranking of the likelihood of off-target interaction to make critical decisions on which compounds to progress, modify or further investigate
• Use cases for Secondary Intelligence™ software

Will Redfern, PhD

Vice President, Quantitative Systems Toxicology and Safety

WillはサターラのQSTSチームを統率し、計算科学アプローチを駆使した医薬品やその他の化学物質の安全性評価に取り組んでいます。He is an experienced safety pharmacologist, having worked at Syntex, Quintiles, and AstraZeneca. 2017年にはSafety Pharmacology SocietyのPresidentを務めました。